Chagas disease serological test performance in U.S. blood donor specimens

51Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Chagas disease affects an estimated 300,000 individuals in the United States. Diagnosis in the chronic phase requires positive results from two different IgG serological tests. Three enzyme-linked immunosorbent assays (ELISAs) (Hemagen, Ortho, and Wiener) and one rapid test (InBios) are FDA cleared, but comparative data in U.S. populations are sparse. We evaluated 500 seropositive and 300 seronegative blood donor plasma samples. Country of birth was known for 255 seropositive specimens, which were grouped into regions as follows: Mexico (n 94), Central America (n 88), and South America (n 73). Specimens were tested by the four FDA-cleared IgG serological assays. Test performance was evaluated by two comparators and latent class analysis. InBios had the highest sensitivity (97.4% to 99.3%) but the lowest specificity (87.5% to 92.3%). Hemagen had the lowest sensitivity (88.0% to 92.0%) but high specificity (99.0% to 100.0%). The level of sensitivity was intermediate for Ortho (92.4% to 96.5%) and Wiener (94.0% to 97.1%); both had high specificity (98.8% to 100.0% and 96.7% to 99.3%, respectively). The levels of antibody reactivity and clinical sensitivity were lowest in donors from Mexico, intermediate in those from Central America, and highest in those from South America. Our findings provide an initial evidence base to improve laboratory diagnosis of Chagas disease in the United States. The best current testing algorithm would employ a high-sensitivity screening test followed by a high-specificity confirmatory test.

References Powered by Scopus

Chagas disease

980Citations
N/AReaders
Get full text

The revised Trypanosoma cruzi subspecific nomenclature: Rationale, epidemiological relevance and research applications

688Citations
N/AReaders
Get full text

Evaluation and treatment of chagas disease in the United States: A systematic review

658Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Evaluation of SARS-CoV-2 serology assays reveals a range of test performance

208Citations
N/AReaders
Get full text

Chagas disease in the united states: A public health approach

181Citations
N/AReaders
Get full text

Recommendations for Screening and Diagnosis of Chagas Disease in the United States

56Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Whitman, J. D., Bulman, C. A., Gunderson, E. L., Irish, A. M., Townsend, R. L., Stramer, S. L., … Bern, C. (2019). Chagas disease serological test performance in U.S. blood donor specimens. Journal of Clinical Microbiology, 57(12). https://doi.org/10.1128/JCM.01217-19

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

64%

Researcher 6

24%

Professor / Associate Prof. 2

8%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 8

42%

Immunology and Microbiology 5

26%

Medicine and Dentistry 3

16%

Arts and Humanities 3

16%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free